{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:09:56Z","timestamp":1780438196659,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"DOI":"10.7759\/cureus.110141","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:59:04Z","timestamp":1780437544000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of Treatment With Cyclosporine Ophthalmic Solution 0.09% on Dry Eye Questionnaire Scores Among Patients With Dry Eye Disease"],"prefix":"10.7759","author":[{"given":"Rana","family":"Taji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King Y","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS DEWS III: management and therapy","volume":"279","author":"Jones L","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, et al.. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025, 279:289-386. 10.1016\/j.ajo.2025.05.039","journal-title":"Am J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2556-5","article-title":"Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa\u00ae) for dry eye disease","volume":"36","author":"Mandal A","year":"2019","unstructured":"Mandal A, Gote V, Pal D, Ogundele A, Mitra AK. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa\u00ae) for dry eye disease. Pharm Res. 2019, 36:36. 10.1007\/s11095-018-2556-5","journal-title":"Pharm Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III: diagnostic methodology","volume":"279","author":"Wolffsohn JS","year":"2025","unstructured":"Wolffsohn JS, Ben\u00edtez-Del-Castillo JM, Loya-Garcia D, et al.. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025, 279:387-450. 10.1016\/j.ajo.2025.05.033","journal-title":"Am J Ophthalmol"},{"key":"ref4","unstructured":"CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09%. Full prescribing information Sun Pharmaceutical Industries, Inc. (2022). Accessed. February 12, 2026: https:\/\/cequa.com\/CequaPI.pdf."},{"key":"ref5","unstructured":"CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09%. Product monograph. Sun Pharmaceutical Industries Limited. (2025). Accessed. April 28, 2026: https:\/\/pdf.hres.ca\/dpd_pm\/00080413.PDF."},{"key":"ref6","unstructured":"Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%. Full prescribing information. Allergan. (2024). Accessed. February 12, 2026: https:\/\/www.rxabbvie.com\/pdf\/restasis_pi.pdf."},{"key":"ref7","unstructured":"Vevye\u00ae (cyclosporine ophthalmic solution) 0.1%. Full prescribing information. Harrow Eye LLC. (2024). Accessed. February 12, 2026: https:\/\/vevye.nyc3.cdn.digitaloceanspaces.com\/files\/VEVYE-Prescribing-Information.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery","volume":"4","author":"Cholkar K","year":"2015","unstructured":"Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol. 2015, 4:1. 10.1167\/tvst.4.3.1","journal-title":"Transl Vis Sci Technol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S175065","article-title":"A Phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber J","year":"2018","unstructured":"Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI. A Phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018, 12:1921-9. 10.2147\/OPTH.S175065","journal-title":"Clin Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg DF","year":"2019","unstructured":"Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019, 126:1230-7. 10.1016\/j.ophtha.2019.03.050","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1305579","article-title":"Impact of dry eye disease treatment on patient quality of life","volume":"11","author":"Lin CW","year":"2024","unstructured":"Lin CW, Lin MY, Huang JW, Wang TJ, Lin IC. Impact of dry eye disease treatment on patient quality of life. Front Med (Lausanne). 2024, 11:1305579. 10.3389\/fmed.2024.1305579","journal-title":"Front Med (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2009.12.010","article-title":"Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses","volume":"33","author":"Chalmers RL","year":"2010","unstructured":"Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye. 2010, 33:55-60. 10.1016\/j.clae.2009.12.010","journal-title":"Cont Lens Anterior Eye"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S583071","article-title":"Effect of cyclosporine ophthalmic solution 0.09% on signs and symptoms of dry eye disease in patients inadequately controlled on cyclosporine ophthalmic emulsion 0.05%: results from a single-arm, open-label, phase 4 study","volume":"20","author":"Johnston J","year":"2026","unstructured":"Johnston J, Adler R, Hessen M, et al.. Effect of cyclosporine ophthalmic solution 0.09% on signs and symptoms of dry eye disease in patients inadequately controlled on cyclosporine ophthalmic emulsion 0.05%: results from a single-arm, open-label, phase 4 study. Clin Ophthalmol. 2026, 20:583071. 10.2147\/OPTH.S583071","journal-title":"Clin Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001989","article-title":"Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and phase 3 studies","volume":"38","author":"Malhotra R","year":"2019","unstructured":"Malhotra R, Devries DK, Luchs J, et al.. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and phase 3 studies. Cornea. 2019, 38:1259-65. 10.1097\/ICO.0000000000001989","journal-title":"Cornea"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0154","article-title":"Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on conjunctival staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and 3 clinical trials","volume":"35","author":"Smyth-Medina R","year":"2019","unstructured":"Smyth-Medina R, Johnston J, Devries DK, et al.. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on conjunctival staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and 3 clinical trials. J Ocul Pharmacol Ther. 2019, 35:388-94. 10.1089\/jop.2018.0154","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman RM","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000, 118:615-21. 10.1001\/archopht.118.5.615","journal-title":"Arch Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.882803","article-title":"Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis","volume":"13","author":"Gao D","year":"2022","unstructured":"Gao D, Da Z, Yang K, Shi Y. Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis. Front Pharmacol. 2022, 13:882803. 10.3389\/fphar.2022.882803","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468356-effects-of-treatment-with-cyclosporine-ophthalmic-solution-009-on-dry-eye-questionnaire-scores-among-patients-with-dry-eye-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:59:06Z","timestamp":1780437546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468356-effects-of-treatment-with-cyclosporine-ophthalmic-solution-009-on-dry-eye-questionnaire-scores-among-patients-with-dry-eye-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.110141","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}